Tags: High Cholesterol | bad cholesterol | LDL cholesterol | evolocumab | PCSK9

New Once-Monthly Drug Cuts Cholesterol

Monday, 17 March 2014 12:37 PM


Amgen Inc said on Monday its experimental new type of cholesterol fighter met the primary goal of a late-stage trial by significantly cutting "bad" LDL cholesterol among patients with a genetic tendency towards very high levels of the artery clogging fat.
 
Amgen said patients given its injectable drug evolocumab once a month on top of standard daily statin treatments showed "clinically meaningful" improvement compared to statins alone after 12 weeks of treatment.
 
Evolocumab works by blocking PCSK9, a naturally occurring protein that keeps LDL levels elevated in the bloodstream. Other drugmakers, including Pfizer Inc and a partnership between Regeneron Inc and Sanofi, are racing with Amgen to complete trials of potentially lucrative anti-PCSK9 antibodies.
 
ALERT: 4 Things You'll Feel Before a Heart Attack


© 2020 Thomson/Reuters. All rights reserved.


   
1Like our page
2Share
Health-News
Amgen Inc said on Monday its experimental new type of cholesterol fighter met the primary goal of a late-stage trial by significantly cutting bad LDL cholesterol among patients with a genetic tendency towards very high levels of the artery clogging fat. Amgen said patients...
bad cholesterol,LDL cholesterol,evolocumab,PCSK9
124
2014-37-17
Monday, 17 March 2014 12:37 PM
Newsmax Media, Inc.
 
Newsmax TV Live

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved